|Articles|February 1, 2001
- Pharmaceutical Executive-12-01-2001
- Volume 0
- Issue 0
Generics Debate Escalates
Calls for change reflect that generic products are a therapeutic mainstay and that patients and providers want earlier access to inexpensive medicines.
Advertisement
Articles in this issue
over 24 years ago
States Target DTC Advertisingover 24 years ago
Transparent Momentover 24 years ago
IFPMA Disputes Doctors Without Boarders Reportover 24 years ago
GSK at Odds with Activistsover 24 years ago
Protecting People Everywhereover 24 years ago
Opening the Door to Japanover 24 years ago
Trade Pact Weakens Patent Protectionsover 24 years ago
EC Questions Dual Pricingover 24 years ago
Genetic Test Results Off Limits-For Nowover 24 years ago
Precious PlasmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AI has Redefined Healthcare Communication — and There’s No Opting Out
2
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
3
Novo Nordisk Signs Deal with Hims & Hers
4
FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer
5